2024-04-27 10:27:00 ET
Summary
- NKTX is now down over 50% from its March 2024 highs.
- The company's pipeline includes NKX019, a CAR-NK cell therapy with potential in cancer and autoimmune disease.
- NKTX has already produced some data with NKX019 in oncology with more data coming mid-year. The work in autoimmune disease is just getting underway in H1'24.
Nkarta Inc's ( NKTX ) stock has pulled back over 50% from the highs of early March 2024. The name might find support in the $6 range looking at the chart, but to see if there might be some news flow to help that out, it's important to look at the company's pipeline of modified NK cells and upcoming catalysts....
Read the full article on Seeking Alpha
For further details see:
Nkarta: Down 50% Since March With A Clinical Catalyst Ahead